Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? (Q34706835)

4 August 2017

1 reference

title

Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? (English)

1 reference

4 August 2017

0 references

Marja-Liisa Dahl

1

1 reference

4 August 2017

1 January 2002

1 reference

Clinical Pharmacokinetics

4 August 2017

1 reference

4 August 2017

41

1 reference

4 August 2017

453-470

1 reference

4 August 2017

7

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200241070-00001

4 August 2017

0 references

cites work

Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene

1 reference

12 December 2020

Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions

1 reference

12 December 2020

Absence of interaction between erythromycin and a single dose of clozapine

1 reference

12 December 2020

Defective N-oxidation of sparteine in man: A new pharmacogenetic defect

1 reference

12 December 2020

Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.

1 reference

12 December 2020

A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity

1 reference

12 December 2020

Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia

1 reference

12 December 2020

Fluvoxamine is a potent inhibitor of cytochrome P4501A2

1 reference

12 December 2020

CYP2D6*10 alleles are not the determinant of the plasma haloperidol concentrations in Asian patients

1 reference

12 December 2020

Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine.

1 reference

12 December 2020

Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations

1 reference

12 December 2020

Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentration

1 reference

12 December 2020

Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles

1 reference

12 December 2020

A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.

1 reference

12 December 2020

Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe

1 reference

12 December 2020

Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro

1 reference

12 December 2020

Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans

1 reference

12 December 2020

Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients.

1 reference

12 December 2020

Debrisoquine oxidation phenotype and neuroleptic-induced dystonic reactions

1 reference

12 December 2020

Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype

1 reference

12 December 2020

Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics.

1 reference

12 December 2020

Metabolism and bioactivation of clozapine by human liver in vitro

1 reference

12 December 2020

Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes

1 reference

12 December 2020

Plasma levels of clozapine and desmethylclozapine are unaffected by concomitant ingestion of grapefruit juice

1 reference

12 December 2020

Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities

1 reference

12 December 2020

Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects

1 reference

12 December 2020

Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.

1 reference

12 December 2020

Polymorphic hydroxylation of debrisoquine

1 reference

12 December 2020

Elevated levels of clozapine in serum after addition of fluvoxamine

1 reference

12 December 2020

Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin.

1 reference

12 December 2020

The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6

1 reference

12 December 2020

Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation.

1 reference

12 December 2020

The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine

1 reference

12 December 2020

Clinical pharmacokinetics of quetiapine: an atypical antipsychotic

1 reference

12 December 2020

Involvement of CYP3A4 in the metabolism of bromperidol in vitro

1 reference

12 December 2020

Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9

1 reference

12 December 2020

Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia

1 reference

12 December 2020

Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.

1 reference

12 December 2020

The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism

1 reference

12 December 2020

Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences

1 reference

12 December 2020

Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine

1 reference

12 December 2020

Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients

1 reference

12 December 2020

Pregnancy-induced changes in drug metabolism in epileptic women

1 reference

12 December 2020

Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes

1 reference

12 December 2020

Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans

1 reference

12 December 2020

Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism

1 reference

12 December 2020

Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations

1 reference

12 December 2020

Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents

1 reference

12 December 2020

Influence of Cyp2D6 Genetic Polymorphism on Ratios of Steady-state Serum Concentration to Dose of the Neuroleptic Zuclopenthixol

1 reference

12 December 2020

In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol.

1 reference

12 December 2020

Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.

1 reference

12 December 2020

Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects

1 reference

12 December 2020

Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia

1 reference

12 December 2020

Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype

1 reference

12 December 2020

Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population

1 reference

12 December 2020

Is diclofenac a valuable CYP2C9 probe in humans?

1 reference

12 December 2020

Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type

1 reference

12 December 2020

Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects.

1 reference

12 December 2020

D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate

1 reference

12 December 2020

Serum Concentrations and Side Effects in Psychiatric Patients During Risperidone Therapy

1 reference

12 December 2020

CYP2D6 mutations and therapeutic outcome in schizophrenic patients

1 reference

12 December 2020

Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population

1 reference

12 December 2020

Pharmacogenetics of classical and new antipsychotic drugs

1 reference

12 December 2020

Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics

1 reference

12 December 2020

The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers

1 reference

12 December 2020

Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole.

1 reference

12 December 2020

Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype

1 reference

12 December 2020

The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol.

1 reference

12 December 2020

Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia

1 reference

12 December 2020

Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment

1 reference

12 December 2020

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations

1 reference

12 December 2020

Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6

1 reference

12 December 2020

Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings

1 reference

12 December 2020

CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia

1 reference

12 December 2020

Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype

1 reference

12 December 2020

Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia.

1 reference

12 December 2020

Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine

1 reference

12 December 2020

Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

1 reference

12 December 2020

Risperidone metabolism and the impact of being a cytochrome P450 2D6 ultrarapid metabolizer

1 reference

12 December 2020

Inhibitory effects of neuroleptics on debrisoquine oxidation in man

1 reference

12 December 2020

Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis

1 reference

12 December 2020

Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin

1 reference

12 December 2020

CYP2C19 genotype and phenotype determined by omeprazole in a Korean population

1 reference

12 December 2020

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

1 reference

12 December 2020

Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes

1 reference

12 December 2020

Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone

1 reference

12 December 2020

Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients

1 reference

12 December 2020

A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

1 reference

12 December 2020

Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients

1 reference

12 December 2020

Absorption, metabolism, and excretion of risperidone in humans.

1 reference

12 December 2020

A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia.

1 reference

12 December 2020

Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians

1 reference

12 December 2020

Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes.

1 reference

12 December 2020

Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities

1 reference

12 December 2020

Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes

1 reference

12 December 2020

The use of caffeine for enzyme assays: a critical appraisal

1 reference

12 December 2020

Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test

1 reference

12 December 2020

Polymorphic hydroxylation of Debrisoquine in man.

1 reference

12 December 2020

Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype

1 reference

12 December 2020

Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting

1 reference

12 December 2020

Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism

1 reference

12 December 2020

Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine

1 reference

12 December 2020

Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers

1 reference

12 December 2020

Debrisoquine oxidation phenotype during neuroleptic monotherapy

1 reference

12 December 2020

Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients

1 reference

12 December 2020

Pharmacokinetics and metabolism of 2-chloro-11-(2-dimethylaminoethoxy)-dibenzo[b,f]thiepine (zotepine) in rat, mouse, dog and man

1 reference

12 December 2020

Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation

1 reference

12 December 2020

Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine

1 reference

12 December 2020

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

1 reference

12 December 2020

Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4

1 reference

12 December 2020

Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population

1 reference

12 December 2020

Interconversion between haloperidol and reduced haloperidol in healthy volunteers

1 reference

12 December 2020

S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians

1 reference

12 December 2020

Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.

1 reference

12 December 2020

Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes

1 reference

12 December 2020

The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population

1 reference

12 December 2020

Noninvasive tests of CYP3A enzymes

1 reference

12 December 2020

CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients

1 reference

12 December 2020

Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin

1 reference

12 December 2020

Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes

1 reference

12 December 2020

Conversion of bromperidol to reduced bromperidol in human liver

1 reference

12 December 2020

Effects of various factors including the CYP2D6 genotype and coadministration of flunitrazepam on the steady-state plasma concentrations of bromperidol and its reduced metabolite.

1 reference

12 December 2020

Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol

1 reference

12 December 2020

Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype

1 reference

12 December 2020

Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients

1 reference

12 December 2020

Biotransformation of Post-Clozapine Antipsychotics

1 reference

12 December 2020

Pharmacokinetic Interaction of Fluvoxamine and Thioridazine in Schizophrenic Patients

1 reference

12 December 2020

Genetic association analysis between CYP2D6*2 allele and tardive dyskinesia in schizophrenic patients

1 reference

12 December 2020

Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype

1 reference

12 December 2020

Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients

1 reference

12 December 2020

CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity

1 reference

12 December 2020

Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans

1 reference

12 December 2020

Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients

1 reference

12 December 2020

Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese

1 reference

12 December 2020

Disposition and biotransformation of the antipsychotic agent olanzapine in humans

1 reference

12 December 2020

Thioridazine cardiotoxicity

1 reference

12 December 2020

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

1 reference

12 December 2020

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans

1 reference

12 December 2020

Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms

1 reference

12 December 2020

A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone

1 reference

12 December 2020

Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations

1 reference

12 December 2020

Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9

1 reference

12 December 2020

10.2165/00003088-200241070-00001

Identifiers

DOI

1 reference

PubMed ID

12083975

Dimensions Publication ID

4 August 2017

0 references

1 reference

PubMed ID

12083975